Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-7560
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMichel, Maurice-
dc.contributor.authorHess, Cornelius-
dc.contributor.authorKaps, Leonard-
dc.contributor.authorKremer, Wolfgang M.-
dc.contributor.authorHilscher, Max-
dc.contributor.authorGalle, Peter R.-
dc.contributor.authorMoehler, Markus-
dc.contributor.authorSchattenberg, Jörn M.-
dc.contributor.authorWörns, Marcus-Alexander-
dc.contributor.authorLabenz, Christian-
dc.contributor.authorNagel, Michael-
dc.date.accessioned2022-08-15T10:28:07Z-
dc.date.available2022-08-15T10:28:07Z-
dc.date.issued2021-
dc.identifier.urihttps://openscience.ub.uni-mainz.de/handle/20.500.12030/7574-
dc.description.abstractMethylglyoxal (MGO) is a highly reactive dicarbonyl species that forms advanced glycation end products (AGEs). The binding of these AGEs to their receptor (RAGE) causes and sustains severe inflammation. Systemic inflammation is postulated to be a major driver in the progression of liver cirrhosis. However, the role of circulating MGO levels in liver cirrhosis remains unknown. In this study, we investigated the serum levels of two dicarbonyl species, MGO and glyoxal (GO) using tandem mass spectrometry (HPLC–MS/MS) and evaluated their association with disease severity. A total of 51 inpatients and outpatients with liver cirrhosis of mixed etiology and different disease stages were included. Elevated MGO levels were seen in an advanced stage of liver cirrhosis (p < 0.001). High MGO levels remained independently associated with impaired liver function, as assessed by the model for end-stage liver disease (MELD) (β = 0.448, p = 0.002) and acute decompensation (AD) (β = 0.345, p = 0.005) scores. Furthermore, MGO was positively correlated with markers of systemic inflammation (IL-6, p = 0.004) and the development of ascites (p = 0.013). In contrast, no changes were seen in GO serum levels. Circulating levels of MGO are elevated in advanced stages of liver cirrhosis and are associated with impaired liver function and liver-related parameters.en_GB
dc.language.isoengde
dc.rightsCC BY*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.titleElevated serum levels of methylglyoxal are associated with impaired liver function in patients with liver cirrhosisen_GB
dc.typeZeitschriftenaufsatzde
dc.identifier.doihttp://doi.org/10.25358/openscience-7560-
jgu.type.dinitypearticleen_GB
jgu.type.versionPublished versionde
jgu.type.resourceTextde
jgu.organisation.departmentFB 04 Medizinde
jgu.organisation.number2700-
jgu.organisation.nameJohannes Gutenberg-Universität Mainz-
jgu.rights.accessrightsopenAccess-
jgu.journal.titleScientific reportsde
jgu.journal.volume11de
jgu.pages.alternative20506de
jgu.publisher.year2021-
jgu.publisher.nameMacmillan Publishers Limited, part of Springer Naturede
jgu.publisher.placeLondonde
jgu.publisher.issn2045-2322de
jgu.organisation.placeMainz-
jgu.subject.ddccode610de
jgu.publisher.doi10.1038/s41598-021-00119-7de
jgu.organisation.rorhttps://ror.org/023b0x485-
Appears in collections:JGU-Publikationen

Files in This Item:
  File Description SizeFormat
Thumbnail
elevated_serum_levels_of_meth-20220815115004627.pdf1.06 MBAdobe PDFView/Open